VTGN News and Press, VistaGen Therapeutics Inc. From 08/07/23

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is one of today's top gainers. The company's shares are currently up 877.38% on the day to $16.42. VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential ...

2023-08-07 09:58:40 ET Are you looking for penny stocks to buy? Are you grappling with the push and pull of skeptics saying penny stocks aren’t worth it or penny stocks are a scam? Day in and day out, there are countless cheap stocks that explode hundreds of percentage points tha...

2023-08-07 09:35:31 ET Vistagen ( NASDAQ: VTGN ) said that a phase 3 study of fasedienol, a nasal spray to treat social anxiety disorder, met its primary and secondary endpoints. The candidate, which has a novel mechanism of action, led to  statistically significant impro...

First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years Statistically significant rapid-onset reduction in patient-reported Subjective Units of Distress Scale (SUDS) score compared to placebo in a public speaking challenge (primary endp...

Vistagen (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced new mechanism of action data from a preclinical t...

Preclinical study of radiolabeled intranasal itruvone in laboratory rats further validates itruvone’s potential to treat major depressive disorder (MDD) without systemic absorption Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the...

Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received a Notice of Allowance from the Canadian...

Oral levodopa is the gold standard treatment for motor symptoms in individuals diagnosed with Parkinson’s disease, despite the risk of dyskinesia (sudden uncontrolled movements) related to long-term use of levodopa Published preclinical data in widely used MPTP non-human primate mo...

Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is releasing its 2023 fiscal year report. Highlights...

2023-06-28 16:32:00 ET VistaGen Therapeutics press release ( NASDAQ: VTGN ): FY GAAP EPS of -$8.51 misses by $0.11 . At March 31, 2023, the Company had cash and cash equivalents of approximately $16.6 million. As of June 27, 2023, the Company had 7,872,479 shares o...